Title : Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

Pub. Date : 1995 Aug 5

PMID : 7623531






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 25 patients with relapsed B-cell lymphomas were evaluated with trace labelled doses (2.5 mg/kg, 185-370 MBq [5-10 mCi]) of 131I-labelled anti-CD20 (B1) antibody in a phase II trial. Iodine-131 keratin 20 Homo sapiens
2 131I-anti-CD20 (B1) antibody therapy produces complete responses of long duration in most patients with relapsed B-cell lymphomas when given at maximally tolerated doses with autologous stem cell rescue. Iodine-131 keratin 20 Homo sapiens